Selective Advantage of NACT in Advanced Ovarian Cancer: A Retrospective Single-Centre Analysis.

Medicina (Kaunas) · 2025 · PMC12388468 · PMID 40870538

Europe PMC DOI

hedged sentence

0.0820

closest p · 1.6× alpha

0.0820

boldest claim

The sentences

borderline significantp = 0.082so close (0.05 < p ≤ 0.1)

In the OS model, NACT showed a non-significant trend towards improved survival (HR = 0.46; 95% CI: 0.14–1.52; p = 0.202), while FIGO IV showed a borderline significant association with worse OS (HR = 2.81; 95% CI: 0.88–8.99; p = 0.082).

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.